Trump vs. Big Pharma – Part 2 : Here Comes Trump as the Hero to Break Down Monopoly! The 2026 Drug Price Revolution (feat. Healthcare Crisis, Insulin Cuts, PBM Overhaul)!

Ever wonder why insulin costs so much? Who’s behind these insane price hikes? What’s really going on with Big Pharma, insurance, and the middlemen driving up costs?

And just when you think it can’t get worse—here comes Trump, the hero with the Rescue plan! Ready to find out how he plans to break Big Pharma’s monopoly and kickstart a revolution in 2026? Hold on tight—Part 2 is about to blow your mind!

Biden Feels the Heat as Election Day Looms

51. As the election got closer and Biden’s approval numbers started slipping, he began to panic.
52. Suddenly, the pharmaceutical industry wasn’t the main issue anymore.

Biden’s Last-Minute Insulin Deal

53. Biden made a major move on insulin, securing a $35 monthly cap for everyone covered by insurance — not just those over 65.
54. Before stepping down, he hid a ticking time bomb in the Inflation Reduction Act, set to go off in 2026.

The ‘Bomb’ That Could Shake Up Drug Prices

55. The bomb? The government would now have a say in drug prices, not just PBMs.
56. And it doesn’t stop with patents.
57. If a drug’s patent lasts for 15 years, the government can start negotiating prices from year 9.
58. When the government joins in, prices could drop by up to 60%.
59. And, oh — new patents get a 20% shorter exclusive period.
60. Pharmaceutical companies will have less time to profit without competition.

Pharma Giants’ Cash Cows Are on the Line

61. There are 15 blockbuster drugs bringing in over $1 billion a year in sales.
62. Of those, 12 will lose their patents before 2030, meaning many of these money-making meds will soon be up for price negotiations.

Biden’s Quick Moves Before the Election

66. Since these provisions don’t kick in until 2026, they didn’t have an immediate impact on the election.
67. With the clock ticking, Biden pressured pharmaceutical companies into slashing prices on popular diabetes drugs to win votes.

The Election Outcome: Biden Out, Trump In

68. Biden lost his re-election bid, and Trump kicked off his second term.
69. Trump brought back his earlier drug price reduction policies that had stalled under Biden.
70. But this time, Trump didn’t waste any time—he went full throttle on drug price cuts right from the start of his second term.

71. On May 12, 2025, Trump signed a game-changing executive order. He said:
    “Tomorrow, at 9 AM in the White House, I’ll be signing one of the most important executive orders in history. Prescription drug prices will drop by 30% to 80%. Americans will pay what the lowest-priced countries pay. Finally, the U.S. will be treated fairly, and Americans will see their medical costs drop like never before.”

The Big Picture: PBM Overhaul and Global Price Link

72. The executive order focused on revamping the PBM system and linking U.S. drug prices to the lowest prices around the globe.
73. While Biden made insulin cheaper, pharmaceutical companies have found ways to make patients pay even more.
74. For example, Jardiance, a diabetes drug, costs $35 in Japan, $70 in Switzerland, but in the U.S., it’s still a whopping $611.
75. Trump fired back: “Pharma donations can make things happen in Washington, but they don’t affect me or the Republican Party.”

Pharma Pushback: “We’ll Quit If You Cut Prices!”

76. Pharmaceutical companies weren’t happy. They threatened to leave programs that help low-income Americans afford meds.
77. They argue that cutting prices will hurt innovation and slow down research and development.
78. Trump hit back, saying, “For years, the world’s wondered why American drug prices are so high. Pharma companies say it’s for R&D costs, but all this cost has been dumped on ‘suckers’ in the U.S. for too long.”

The Battle Spreads: A Fight for Fair Prices

79. What started as a battle over drug prices is now expanding into a full-fledged war against the healthcare cartel.
80. The U.S. offers Medicare for seniors, but private insurance remains the main game in town.
81. These private insurance companies are maximizing their profits by integrating insurance, medical services, and patient data.

UnitedHealth CEO’s Shocking Death and the Message Left Behind

82. In December 2024, Brian Thompson, CEO of UnitedHealth, was shot and killed on the streets of New York.
83. The shooter left a chilling message: “These parasites must pay the price,” and the shell casing had words like “delay,” “deny,” and “defend” etched into it.
84. These words? Classic tactics used by insurance companies to deny claims.
85. UnitedHealth is the largest private health insurance company in the U.S.
86. They insure 51 million Americans, which is about 15% of the population, and rake in $400 billion a year in premiums.
87. They also own subsidiaries that handle pharmacy, healthcare services, and medical data.

The Pushback on Insurance: UnitedHealth’s Growing Controversy

88. OptumHealth, a subsidiary, employs 90,000 doctors and provides services like remote healthcare and medical finance.
89. OptumRX is a major PBM company.
90. Along with Express Scripts and CVS Health, OptumRX controls a whopping 80% of the PBM market in the U.S.
91. Optum Insight, another subsidiary, has access to health data for 300 million Americans.
92. UnitedHealth uses this data to decide which claims get paid out.

UnitedHealth’s Claim Denial Rate: A Look Inside the Numbers

93. The insurance claim denial rate in the U.S. is about 15%, twice as high as in many other countries.
94. Though most claims are paid out, the 15% denial rate can add up.
95. A major reason for denials is unreported pre-existing conditions.
96. If you don’t disclose a pre-existing condition when applying for insurance, your claims can be rejected.
97. UnitedHealth’s claim denial rate has skyrocketed since Brian Thompson became CEO. It went from 10.9% to 32%.

Profits and Controversy: The UnitedHealth Dilemma

98. With all the claim denials, UnitedHealth’s profits have grown, but so has its bad reputation.
99. In the U.S., it’s common for patients to check if their insurance will cover treatment before they even go to the doctor.
100. After Thompson took the helm, UnitedHealth’s claim denial rate soared, and its infamy grew right along with it.
101. Even after Thompson’s death, UnitedHealth’s new CEO, Andrew Witty, declared that Thompson’s legacy would continue.
102. UnitedHealth plans to keep using complex criteria and AI to deny claims wherever possible.

Why People Stick With UnitedHealth Despite the Backlash

105. Despite its reputation, many still choose UnitedHealth, simply because it’s one of the biggest players in the market.
106. Private health insurance in the U.S. is often tied to specific doctors and hospitals.
107. Even if you have insurance, it won’t do you any good if your doctor or hospital doesn’t accept it.
108. That’s why many people opt for the top insurers, which have deals with a large number of hospitals and doctors.
109. Sure, people grumble, but they stick with the giants because it’s just easier.

Trump’s Next Moves: Healthcare and Big Pharma in His Crosshairs

110. The real question for Trump’s second term is how he’ll take on these healthcare battles.
111. The issue of high U.S. drug prices won’t be solved just by attacking domestic players—it’s a global issue.
112. Two major players, Roche and Novartis, control 15% of the global new drug pipeline.
113. These Swiss companies charge more for drugs in the U.S. than they do in the EU—often double.
114. Switzerland wanted a 10% tariff on $150 billion in investments, but Trump slapped them with a 39% tariff instead.
115. Trump sent letters to 19 global pharmaceutical companies, demanding they lower U.S. drug prices to the lowest levels.
116. One of the reasons for the 39% tariff on Swiss exports? Pressure for them to lower U.S. drug prices.

Trump’s Power Play: Can Executive Orders and Tariffs Tame Big Pharma?

Here’s the real question: Can Trump’s audacious mix of executive orders and trade tariffs really force Big Pharma and private insurers to play by his rules? With the world’s most powerful pharmaceutical companies and insurance giants pulling the strings behind the scenes, Trump’s daring moves are shaking things up like never before. Is this the beginning of a revolution in America’s healthcare system, or just another power struggle that will fizzle out? This is where the stakes get truly high, and the showdown for control over prescription prices could change everything—if Trump can pull it off. Ready for the inside scoop on the most intense healthcare battle of our time? Let’s break it down!